TECH's profitability deteriorated substantially with net income and operating income both declining meaningfully while SG&A expenses increased over 25%.
The company appears to be facing significant operational challenges as profitability declined sharply despite what seems to be an established business model in protein sciences and diagnostics. The simultaneous reduction in capital expenditures suggests management may be pulling back on growth investments while struggling with cost control, as evidenced by the substantial increase in SG&A expenses.
TECH's financial performance weakened considerably with both net income and operating income declining substantially year-over-year. SG&A expenses grew over 25% to $588.5M, indicating potential cost control issues or significant investments that have not yet translated to profitability. The company also meaningfully reduced capital expenditures from $62.9M to $31.0M, suggesting either improved efficiency or a pullback in growth investments during this challenging period.
Net income declined 56.3% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 50.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Current liabilities rose 10.3% — increased short-term obligations, watch current ratio.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →